Autologous Conditioned Plasma Market will exhibit an impressive CAGR of 11% over the forecast period (2020-2030) - Persistence Market Research

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Increasing geriatric population and their preference for minimally-invasive / non-surgical treatments over surgical treatments is giving impetus to the growth of the autologous conditioned plasma therapy market. Autologous conditioned plasma therapy is an efficient, simple, and minimally-invasive method that denotes an appropriate biological approach for ensuring tissue healing in a very short period of time. This therapy is used extensively across Europe and the U.S. for the treatment of orthopaedic-related injuries, and is now becoming popular across other regions as well.

Persistence Market Research predicts that, the global autologous conditioned plasma therapy market will exhibit an impressive CAGR of 11% over the forecast period (2020-2030), to be valued at around US$ 1.2 Bn by the end of 2030.

Key Takeaways from Autologous Conditioned Plasma Therapy Market Study

    --  By composition, pure platelet-rich fibrin (P-PRF) is expected to
        dominate the global autologous conditioned plasma therapy market during
        the forecast period, owing to high efficacy of the composition in
        accelerating healing.
    --  In terms of source, the autologous platelet-rich plasma segment is
        expected to gain more than 3/4 of the autologous conditioned plasma
        therapy market share by 2030. Preference for the autologous
        platelet-rich plasma source is due to less immune reaction and side
    --  By indication, cosmetic surgery is expected to hold a major revenue
        share in the global autologous conditioned plasma therapy market, owing
        to the rising trend for facial appearance enhancement treatments.
    --  Under the end user segmentation, specialty clinics and orthopaedic &
        trauma centres are expected to collectively gain more than 2/3 of the
        market share by 2030.
    --  North America is the highest revenue generating market by region due to
        the launch of new products and rising adoption of PRP therapies in
        orthopedic surgeries, with an increasing elderly population.
    --  The COVID-19 pandemic has negatively impacted the global autologous
        conditioned plasma therapy market. Due to the outbreak, many companies
        are focusing on finding a possible treatment / vaccine for COVID-19.
        Also, as the spread of coronavirus is increasing, manufacturing
        industries are being shut around the world due to global restrictions,
        causing an unusual technology and business model transformation.

Get PDF Brochure for Research Insights at:

"Rising prevalence of orthopedic conditions along with increasing utilization of platelet-rich plasma in cosmetic surgeries are expected to propel the growth of the global autologous conditioned plasma therapy market," says a PMR analyst.

Get Customization on this Report:

Business Strategies by Market Leaders Coupled with Improved Healthcare Access to Drive Market Growth

Increasing investments in the healthcare sector in emerging countries are anticipated to boost the global autologous conditioned plasma therapy market in these regions. Leading manufacturers in the global autologous conditioned plasma therapy market are extensively focusing on expansion of their product portfolios by undergoing new product developments and approvals, and entering into collaborations, mergers, and acquisitions.

For instance, in March, 2019, Stryker Corporation acquired OrthoSpace, Ltd., a privately-held company of Caesarea, Israel, to expand its business in MEA.

Request for Full Report Access:

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the autologous conditioned plasma therapy market in its latest study, presenting historical demand assessment from 2015 - 2019 and projections from 2020 - 2030, on the basis of composition (pure platelet-rich plasma (P-PRP), pure platelet-rich fibrin (P-PRF), leukocyte- and platelet-rich plasma (LPRP), and leukocyte- and platelet-rich fibrin (L-PRF)), source (autologous platelet-rich plasma, allogeneic platelet-rich plasma, and homologues platelet-rich plasma), indication (skin ulcers, bone fractures and grafts, prostheses surgeries, oral implantology, sports injuries & trauma, cosmetic surgeries, and others), and end user (hospitals, ambulatory surgical centres, specialty clinics, orthopedic & trauma centres, research Institutes, and others), across seven key regions.

Browse Research Release at:

Browse End-to-end Market: Life Sciences & Transformational Health

Related Reports:

    --  Surgical And Respiratory Masks Market:
    --  Disinfection Robot Market:

About Persistence Market Research


Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Rajendra Singh
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
United States
USA - Canada Toll-Free: 800-961-0353
Visit Our Website:
Content Source:

View original content:

SOURCE Persistence Market Research Pvt. Ltd.